ClearPoint Neuro, Inc. Quarterly report pursuant to sections 13 or 15(d)

Quarterly report pursuant to sections 13 or 15(d)

Note 8 - Stockholders' Equity (Tables)

Note 8 - Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2012

Impact of Conversions to Common Stock [Table Text Block]

	Impact to Balance Sheet								Increase in
	Before Conversions		Impact of Conversions			After Conversions			Common Shares Outstanding

Impact on assets
Deferred costs	$	799,123	$	(799,123	)	$	-			-

Impact on liabilities and equity
Accrued interest on converted notes	$	974,311	$	(974,311	)	$	-			1,092,559
Summer 2011 Notes, net		904,397		(904,397	)		-			2,183,334
March 2010 Notes, net		4,057,500		(4,057,500	)		-			4,071,000
2011 Unit Offering Notes, net		4,367,482		(4,367,482	)		-			9,050,834
Total impact on liabilities		10,303,690		(10,303,690	)		-			16,397,727
Series A convertible preferred stock		7,965,000		(7,965,000	)		-			7,965,000
Additional paid-in capital and common stock		-		19,345,209			19,345,209			-
Accumulated deficit		-		(1,875,642	)		(1,875,642	)		-
Total impact on equity		7,965,000		9,504,567			17,469,567			7,965,000
Total impact on liabilities and equity	$	18,268,690	$	(799,123	)	$	17,469,567			24,362,727

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

	Shares			Weighted - Average Exercise Price
Outstanding, January 1, 2012		3,679,977		$	2.05
Granted		2,797,400			1.02
Exercised, including 16,000 shares withheld on net settled exercises		(30,000	)		1.80
Forfeited		(315,250	)		2.16
Outstanding, September 30, 2012		6,132,127			1.58

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Dividend yield		0%
Expected Volatility		45.2%
Risk free Interest rates	0.83%	-	1.13%
Expected lives (years)		6.0

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

	Three Months Ended September 30,			Nine Months Ended September 30,
	2012	2011		2012		2011
$	299,083	$	248,540	$	842,645	$	757,200

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

	Shares			Weighted - Average Exercise Price
Outstanding, January 1, 2012		1,922,944		$	0.43
Issued		7,607,071			1.05
Exercised, including 158,078 shares withheld on net settled exercises		(584,768	)		0.69
Outstanding, September 30, 2012		8,945,247			0.94

Assumptions Used in Calculating Fair Value of Warrants Issued [Table Text Block]

Dividend yield		0%
Expected Volatility	41.3%	-	49.0%
Risk free Interest rates	0.19%	-	0.93%
Expected lives (years)	1.7	-	5.0

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References + Details

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details